Skip to content

A Phase IV, single dose JENVAC (Inactivated JE Vaccine) vs. Chinese SA-14-14-2 (Live JE Vaccine) vaccine

A Phase IV, single dose, openlabelled, comparative, randomized controlled study to evaluate the immunogenicity and safety of BBILâ??s JENVAC (Inactivate JE Vaccine) vs. Chinese SA-14- 14-2 (Live JE Vaccine) vaccine in healthy volunteers â?? Immunogenicity and safety following booster dose after 2 year. - JENVAC Single Dose Extension study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/05/006909
Enrollment
360
Registered
2016-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: JENVAC: purified inactivated JE vaccine, JENVAC manufactured By BBIL, Liquid 0.5mL of JENVAC will be injected as single dose on day 0 by intramuscular route. Control Intervention1: SA 1

Sponsors

Bharat Biotech International Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy volunteers of 1 to 15 years age group (inclusive) without significant medical history or abnormal findings at screening 2.Parents/legal representative willing to give signed written Informed Consent. 3.Available for all study related visits and procedures for the entire duration of the study, without any known exposure to JE prior to the first screening visit based on previous clinical history.

Exclusion criteria

Exclusion criteria: 1.Subjects with the age less than 1 year or more than 15 years. 2.Fever of any origin of duration more than 3 days within one month prior to screening or on the day of screening. 3.History of malaise, headache, anorexia at the time of screening or during the administration of the vaccine under study. 4.Past history of JE infection. 5.Life threatening or serious cardiac (NYHA grades III-IV heart failure), respiratory gastrointestinal, Hepatic, renal, Endocrine, haematological or immune disorders. 6.History of allergic diseases. 7.Any confirmed or suspected immunosuppressive or immunodeficient condition 8.Use of any marketed or investigational or herbal medicine or non-registered drug or vaccine for JE or other vaccine in the past 2 months. 9.Previous history of hypersensitive reaction to vaccine or vaccine component.

Design outcomes

Primary

MeasureTime frame
GMT and seroconversion of JE antibodies on day 28±2 (days) Timepoint: 28±2 (days)

Secondary

MeasureTime frame
GMT and seroconversion on days 56±7 (days), 90±10(days), 180±15(days), 360±15(days)Timepoint: 56±7(days), 90±10(days), 180±15(days), 360±15(days)

Countries

India

Contacts

Public ContactDr Binod Sah

Bharat Biotech International Limited

binod3161@bharatbiotech.com04023480567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026